Yamagata T, Momoi M Y, Murai K, Ikematsu K, Suwa K, Sakamoto K, Fujimura A
Department of Pediatrics, Jichi Medical School, Minamikawachi-machi, Tochigi, Japan.
Ther Drug Monit. 1998 Aug;20(4):396-400. doi: 10.1097/00007691-199808000-00008.
Serum concentrations of valproic acid (VPA) were reduced to 0% to 40% of the original levels by concomitant use with panipenem-betamipron (PAM-BP) in three patients. The serum VPA level began to decrease 2 days after the administration of PAPM-BP, and it began to increase within 24 hours of the last dose. The rapid change in the serum VPA level suggests the existence of unique and as yet unknown mechanisms of interaction between VPA and PAPM-BP. Epileptic seizures developed in two of the three patients during PAPM-BP use, which signaled the dangers of PAPM-BP administration to patients concomitantly administered VPA. PAPM-BP should not be used in patients administered VPA.
在三名患者中,丙戊酸(VPA)与帕尼培南倍他米隆(PAM - BP)同时使用时,血清浓度降至原来水平的0%至40%。血清VPA水平在给予帕尼培南倍他米隆后2天开始下降,并在最后一剂后的24小时内开始上升。血清VPA水平的快速变化表明VPA与帕尼培南倍他米隆之间存在独特且尚未明确的相互作用机制。三名患者中有两名在使用帕尼培南倍他米隆期间出现癫痫发作,这表明对同时服用VPA的患者给予帕尼培南倍他米隆存在风险。服用VPA的患者不应使用帕尼培南倍他米隆。